Reference is made to stock exchange notice 21 November 2014 regarding issuance of convertible loan in favour of Dag Dvergsten AS.

Dag Dvergsten AS has today sent a conversion notice to CellCura whereby Dag Dvergsten AS converts NOK 9 500 000 of its convertible loan into shares in the CellCura at a subscription price of NOK 0.20 per share. Consequently, the share capital will be increased with NOK 9 500 000 by the issuance of 47 500 000 new shares.

Following registration of the share capital increase in the Norwegian Register of Business Enterprises, the share capital of CellCura will be NOK 10 804 100 divided into 54 020 500 shares, each with a nominal value of NOK 0.20.

Oslo, 19 December 2014

CellCura ASA
Tore Viana-Rønningen
Chief Executive Officer
Phone: + 47 911 08 693

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

distributed by